Sanjiv J Shah Selected Research

Mineralocorticoid Receptor Antagonists

11/2021	Association of Hyper-Polypharmacy With Clinical Outcomes in Heart Failure With Preserved Ejection Fraction.
11/2021	Spironolactone in Patients With an Echocardiographic HFpEF Phenotype Suggestive of Cardiac Amyloidosis: Results From TOPCAT.
1/2021	Prognostic Value of Minimal Left Atrial Volume in Heart Failure With Preserved Ejection Fraction.
1/2021	Diagnostic and prognostic implications of heart failure with preserved ejection fraction scoring systems.
1/2020	Myocardial Infarction in Heart Failure With Preserved Ejection Fraction: Pooled Analysis of 3 Clinical Trials.
1/2020	Leucocyte count predicts cardiovascular risk in heart failure with preserved ejection fraction: insights from TOPCAT Americas.
1/2020	Variation in clinical and patient-reported outcomes among complex heart failure with preserved ejection fraction phenotypes.
12/2019	Influence of Age on Efficacy and Safety of Spironolactone in Heart Failure.
1/2019	Efficacy and Safety of Spironolactone in Patients With HFpEF and Chronic Kidney Disease.
1/2019	Impact of Malnutrition Using Geriatric Nutritional Risk Index in Heart Failure With Preserved Ejection Fraction.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Sanjiv J Shah Research Topics

Disease

149	Heart Failure 08/2022 - 02/2006
26	Cardiomyopathies (Cardiomyopathy) 01/2022 - 01/2017
16	Atherosclerosis 06/2021 - 08/2013
15	Cardiovascular Diseases (Cardiovascular Disease) 01/2022 - 01/2015
15	Inflammation (Inflammations) 01/2022 - 11/2011
15	Atrial Fibrillation 01/2022 - 01/2014
15	Hypertension (High Blood Pressure) 01/2022 - 10/2012
12	Pulmonary Hypertension 01/2021 - 07/2009
11	Fibrosis (Cirrhosis) 01/2021 - 11/2015
10	Heart Diseases (Heart Disease) 01/2022 - 10/2012
8	Hypotension (Low Blood Pressure) 11/2021 - 05/2012
8	Hyperkalemia 11/2021 - 04/2014
8	Heart Arrest (Cardiac Arrest) 11/2021 - 04/2014
8	Systemic Scleroderma (Systemic Sclerosis) 01/2021 - 02/2010
8	Pulmonary Arterial Hypertension 10/2018 - 05/2008
7	Amyloidosis 11/2021 - 12/2016
7	Dyspnea (Shortness of Breath) 01/2021 - 02/2007
7	Chronic Renal Insufficiency 01/2021 - 01/2014
7	Left Ventricular Dysfunction 04/2018 - 02/2006
6	Obesity 01/2022 - 08/2017
6	Diabetes Mellitus 12/2019 - 09/2009
6	HIV Infections (HIV Infection) 12/2019 - 01/2018
6	Infections 04/2018 - 03/2013
5	Insulin Resistance 01/2022 - 10/2016
5	Coronary Artery Disease (Coronary Atherosclerosis) 01/2021 - 01/2014
4	Albuminuria 11/2021 - 01/2017
4	Edema (Dropsy) 01/2021 - 12/2016
4	Coronary Disease (Coronary Heart Disease) 01/2020 - 01/2008
4	Hypokalemia 01/2019 - 04/2014
3	Necrosis 01/2022 - 04/2018
3	Transthyretin-Related Hereditary Amyloidosis 01/2022 - 06/2017
3	Chronic Kidney Failure (Chronic Renal Failure) 01/2022 - 01/2016
3	Vascular Diseases (Vascular Disease) 01/2021 - 02/2010
3	Carotid Stenosis (Carotid Artery Stenosis) 12/2019 - 01/2019
3	Disease Progression 01/2019 - 08/2011
3	Stroke (Strokes) 01/2017 - 07/2015
3	Myocardial Infarction 01/2016 - 04/2007
2	Type 2 Diabetes Mellitus (MODY) 01/2022 - 01/2021
2	Breast Neoplasms (Breast Cancer) 01/2022 - 10/2018
2	Hyperlipidemias (Hyperlipidemia) 11/2021 - 01/2021
2	Metabolic Syndrome (Dysmetabolic Syndrome X) 11/2021 - 11/2019
2	Paroxysmal Dyspnea (Paroxysmal Nocturnal Dyspnea) 01/2021 - 12/2016
2	Respiratory Sounds (Crackle) 01/2021 - 01/2019

Drug/Important Bio-Agent (IBA)

32	Mineralocorticoid Receptor AntagonistsIBA 11/2021 - 03/2013
27	Brain Natriuretic Peptide (Natrecor)FDA Link 01/2022 - 02/2007
26	Biomarkers (Surrogate Marker)IBA 01/2022 - 09/2009
21	Spironolactone (Aldactone)FDA LinkGeneric 11/2021 - 03/2013
15	Natriuretic PeptidesIBA 06/2021 - 12/2015
14	CreatinineIBA 01/2021 - 05/2008
13	sacubitril and valsartan sodium hydrate drug combinationIBA 01/2022 - 08/2016
13	pro-brain natriuretic peptide (1-76)IBA 01/2022 - 10/2018
12	Prealbumin (Transthyretin)IBA 01/2022 - 12/2016
10	SodiumIBA 01/2022 - 10/2013
10	Amyloid (Amyloid Fibrils)IBA 01/2022 - 12/2016
10	DiureticsIBA 01/2022 - 09/2009
9	Glucose (Dextrose)FDA LinkGeneric 01/2022 - 01/2016
8	AlbuminsIBA 01/2021 - 02/2010
7	Soluble Guanylyl CyclaseIBA 10/2020 - 12/2015
7	C-Reactive ProteinIBA 01/2020 - 02/2006
6	paragonIBA 01/2022 - 12/2019
6	Plasminogen Activator Inhibitor 1IBA 11/2021 - 11/2016
6	vericiguatIBA 10/2020 - 12/2015
5	tafamidisIBA 01/2022 - 06/2017
5	salicylhydroxamic acid (SHAM)IBA 01/2022 - 01/2018
5	Biological ProductsIBA 01/2022 - 01/2017
5	Type 5 Cyclic Nucleotide PhosphodiesterasesIBA 01/2021 - 01/2019
5	Pharmaceutical PreparationsIBA 01/2020 - 01/2016
5	Gonadal Steroid Hormones (Sex Hormones)IBA 12/2019 - 01/2018
4	Valsartan (Vals)FDA Link 01/2022 - 10/2019
4	Insulin (Novolin)FDA Link 01/2022 - 11/2017
4	Nitric Oxide (Nitrogen Monoxide)FDA Link 06/2021 - 07/2016
4	Neprilysin (Neutral Endopeptidase)IBA 01/2020 - 07/2016
4	Hemoglobins (Hemoglobin)IBA 10/2018 - 02/2010
4	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 07/2016 - 04/2007
3	high fluorescent intermediate IIIBA 01/2022 - 01/2020
3	Triglycerides (Triacylglycerol)IBA 01/2022 - 12/2019
3	Proteins (Proteins, Gene)FDA Link 01/2022 - 11/2020
3	dapagliflozinIBA 01/2022 - 01/2021
3	CholesterolIBA 01/2022 - 01/2016
3	HDL CholesterolIBA 01/2022 - 12/2019
3	Sodium-Glucose Transporter 2 InhibitorsIBA 11/2021 - 11/2017
3	Guanosine Monophosphate (5' Guanylic Acid)IBA 06/2021 - 07/2016
3	Antihypertensive Agents (Antihypertensives)IBA 01/2021 - 01/2016
3	PotassiumIBA 01/2021 - 01/2015
3	Uric Acid (Urate)IBA 03/2020 - 01/2019
3	NitritesIBA 11/2018 - 07/2016
3	NitratesIBA 11/2017 - 12/2015
3	4-S-(propionic acid)sulfidocyclophosphamide (PASP)IBA 06/2017 - 05/2011
3	Transcription Factors (Transcription Factor)IBA 01/2017 - 11/2016
3	Carbon MonoxideIBA 03/2013 - 02/2010
2	empagliflozinIBA 01/2022 - 11/2017
2	Enalapril FDA LinkGeneric 01/2022 - 08/2016
2	AdipokinesIBA 01/2022 - 10/2017
2	CalciumIBA 11/2021 - 01/2021
2	trimethyloxamine (trimethylamine N-oxide)IBA 01/2021 - 01/2018
2	CanagliflozinIBA 01/2021 - 10/2019

Therapy/Procedure

53	Therapeutics 08/2022 - 04/2007
6	Precision Medicine 06/2017 - 10/2012
3	Stem Cell Transplantation 11/2014 - 08/2011
2	Polypharmacy 11/2021 - 05/2016